The Acinetobacter baumannii two-component system aders regulates genes required for multidrug efflux, biofilm formation, and virulence in a strain-specific manner

mBio

Volumn 7, Issue 2, 2016, Pages

  Richmond, Grace E ^a   Evans, Laura P ^a   Anderson, Michele J ^b   Wand, Matthew E ^c   Bonney, Laura C ^c   Ivens, Alasdair ^d   Chua, Kim Lee ^e   Webber, Mark A ^a   Mark Sutton, J ^c   Peterson, Marnie L ^b   Piddock, Laura J V ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF MINNESOTA   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACINETOBACTER BAUMANNII; ADEABC GENE; ADEB GENE; ADERS GENE; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BIOFILM; COM GENE; CONTROLLED STUDY; EX VIVO STUDY; GALLERIA MELLONELLA; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOSS; GENETIC SUSCEPTIBILITY; NONHUMAN; PGAC GENE; PIL GENE; PRIORITY JOURNAL; RNA SEQUENCE; ACINETOBACTER INFECTION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; SPECIES DIFFERENCE; VIRULENCE;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARRIER PROTEIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; SPECIES SPECIFICITY; VIRULENCE;

EID: 84965161649     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00430-16     Document Type: Article

References (60)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538–582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. 1998. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 36:1938–1941.
3. Catalano M, Quelle LS, Jeric PE, Di Martino A, Maimone SM. 1999. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect 42:27–35. http://dx.doi.org/10.1053/jhin.1998.0535.
4. Gaddy JA, Tomaras AP, Actis LA. 2009. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun 77:3150–3160. http://dx.doi.org/10.1128/IAI.00096-09.
5. Tomaras AP, Flagler MJ, Dorsey CW, Gaddy JA, Actis LA. 2008. Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. Microbiology 154:3398-3409. http://dx.doi.org/10.1099/mic.0.2008/019471-0.
6. Goh HM, Beatson SA, Totsika M, Moriel DG, Phan M-D, Szubert J, Runnegar N, Sidjabat HE, Paterson DL, Nimmo GR, Lipman J, Schembri MA. 2013. Molecular analysis of the Acinetobacter baumannii biofilmassociated protein. Appl Environ Microbiol 79:6535-6543 http://dx.doi.org/10.1128/aem.01402-13.
7. Choi AH, Slamti L, Avci FY, Pier GB, Maira-Litrán T. 2009. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol 191:5953–5963. http://dx.doi.org/10.1128/JB.00647-09.
8. Yoon EJ, Courvalin P, Grillot-Courvalin C. 2013. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 57:2989-2995. http://dx.doi.org/10.1128/AAC.02556-12.
9. Roca I, Espinal P, Vila-Farrés X, Vila J. 2012. The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drugresistant menace. Front Microbiol 3:148. http://dx.doi.org/10.3389/fmicb.2012.00148.
10. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie JM. 2006. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2:e7. http://dx.doi.org/10.1371/journal.pgen.0020007.
11. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5:939–951. http://dx.doi.org/10.1038/nrmicro1789.
12. Stewart PS, William Costerton J. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135–138. http://dx.doi.org/10.1016/S0140-6736(01)05321-1.
13. Mah TF, O’Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9:34-39. http://dx.doi.org/10.1016/S0966-842X(00)01913-2.
14. Conlon BP, Rowe SE, Lewis K. 2015. Persister cells in biofilm associated infections. Adv Exp Med Biol 831:1–9. http://dx.doi.org/10.1007/978-3-319-09782-4_1.
15. de la Fuente-Núñez C, Reffuveille F, Fernández L, Hancock RE. 2013. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 16: 580–589. http://dx.doi.org/10.1016/j.mib.2013.06.013.
16. Cabral MP, Soares NC, Aranda J, Parreira JR, Rumbo C, Poza M, Valle J, Calamia V, Lasa I, Bou GN. 2011. Proteomic and functional analyses reveal a unique lifestyle for Acinetobacter baumannii biofilms and a key role for histidine metabolism. J Proteome Res 10:3399–3417. http://dx.doi.org/10.1021/pr101299j.
17. Rumbo-Feal S, Gómez MJ, Gayoso C, Álvarez-Fraga L, Cabral MP, Aransay AM, Rodríguez-Ezpeleta N, Fullaondo A, Valle J, Tomás M, Bou G, Poza M. 2013. Whole transcriptome analysis of Acinetobacter baumannii assessed by RNA-sequencing reveals different mRNA expression profiles in biofilm compared to planktonic cells. PLoS One 8:e72968. http://dx.doi.org/10.1371/journal.pone.0072968.
18. Otto M. 2008. Staphylococcal biofilms. Curr Top Microbiol Immunol 322:207–228. http://dx.doi.org/10.1007/978-3-540-75418-3_10.
19. Anderson GG, Moreau-Marquis S, Stanton BA, O’Toole GA. 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 76:1423–1433. http://dx.doi.org/10.1128/IAI.01373-07.
20. Anderson MJ, Lin YC, Gillman AN, Parks PJ, Schlievert PM, Peterson ML. 2012. Alpha-toxin promotes Staphylococcus aureus mucosal biofilm formation. Front Cell Infect Microbiol 2:64. http://dx.doi.org/10.3389/fcimb.2012.00064.
21. de Breij A, Gaddy J, van der Meer J, Koning R, Koster A, van den Broek P, Actis L, Nibbering P, Dijkshoorn L. 2009. CsuA/BABCDE-dependent pili are not involved in the adherence of Acinetobacter baumannii ATCC 19606T to human airway epithelial cells and their inflammatory response. Res Microbiol 160:213–218. http://dx.doi.org/10.1016/j.resmic.2009.01.002.
22. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. 2004. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48:3298-3304. http://dx.doi.org/10.1128/AAC.48.9.3298-3304.2004.
23. West AH, Stock AM. 2001. Histidine kinases and response regulator proteins in two-component signaling systems. Trends Biochem Sci 26: 369–376. http://dx.doi.org/10.1016/S0968-0004(01)01852-7.
24. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, Dossat C, Gas S, Kreimeyer A, Lenoble P, Oztas S, Poulain J, Segurens B, Robert C, Abergel C, Claverie JM, Raoult D, Médigue C, Weissenbach J, Cruveiller S. 2008. Comparative analysis of acinetobacters: three genomes for three lifestyles. PLoS One 3:e1805. http://dx.doi.org/10.1371/journal.pone.0001805.
25. Richmond GE, Chua KL, Piddock LJ. 2013. Efflux in Acinetobacter baumannii can be determined by measuring accumulation of H33342 (bisbenzimide). J Antimicrob Chemother 68:1594-1600 http://dx.doi.org/10.1093/jac/dkt052.
26. Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, Underwood A, Gaulton T, Thomas CP, Doumith M, Livermore DM, Woodford N. 2011. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother 66:1499–1503. http://dx.doi.org/10.1093/jac/dkr168.
27. de Breij A, Haisma EM, Rietveld M, El Ghalbzouri A, van den Broek PJ, Dijkshoorn L, Nibbering PH. 2012. Three-dimensional human skin equivalent as a tool to study Acinetobacter baumannii colonization. Antimicrob Agents Chemother 56:2459-2464. http://dx.doi.org/10.1128/AAC.05975-11.
28. Amin IM, Richmond GE, Sen P, Koh TH, Piddock LJ, Chua KL. 2013. A method for generating marker-less gene deletions in multidrugresistant Acinetobacter baumannii. BMC Microbiol 13:158. http://dx.doi.org/10.1186/1471-2180-13-158.
29. Anderson MJ, Parks PJ, Peterson ML. 2013. A mucosal model to study microbial biofilm development and anti-biofilm therapeutics. J Microbiol Methods 92:201–208. http://dx.doi.org/10.1016/j.mimet.2012.12.003.
30. Anderson MJ, Scholz MT, Parks PJ, Peterson ML. 2013. Ex vivo porcine vaginal mucosal model of infection for determining effectiveness and toxicity of antiseptics. J Appl Microbiol 115:679-688. http://dx.doi.org/10.1111/jam.12277.
31. Miyata S, Casey M, Frank DW, Ausubel FM, Drenkard E. 2003. Use of the Galleria mellonella caterpillar as a model host to study the role of the type III secretion system in Pseudomonas aeruginosa pathogenesis. Infect Immun 71:2404-2413. http://dx.doi.org/10.1128/IAI.71.5.2404-2413.2003.
32. Jander G, Rahme LG, Ausubel FM. 2000. Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects. J Bacteriol 182:3843–3845. http://dx.doi.org/10.1128/JB.182.13.3843-3845.2000.
33. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53: 2605–2609. http://dx.doi.org/10.1128/AAC.01533-08.
34. Tatusov RL, Galperin MY, Natale DA, Koonin EV. 2000. The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Res 28:33–36. http://dx.doi.org/10.1093/nar/28.1.33.
35. Bahar O, Goffer T, Burdman S. 2009. Type IV pili are required for virulence, twitching motility, and biofilm formation of Acidovorax avenae subsp. citrulli. Mol Plant Microbe Interact 22:909–920. http://dx.doi.org/10.1094/MPMI-22-8-0909.
36. Gaddy JA, Arivett BA, McConnell MJ, López-Rojas R, Pachón J, Actis LA. 2012. Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice. Infect Immun 80:1015–1024. http://dx.doi.org/10.1128/IAI.06279-11.
37. Wilharm G, Piesker J, Laue M, Skiebe E. 2013. DNA uptake by the nosocomial pathogen Acinetobacter baumannii occurs during movement along wet surfaces. J Bacteriol 195:4146–4153. http://dx.doi.org/10.1128/JB.00754-13.
38. Harding CM, Tracy EN, Carruthers MD, Rather PN, Actis LA, Munson RS. 2013. Acinetobacter baumannii strain M2 produces type IV pili which play a role in natural transformation and twitching motility but not surface-associated motility. mBio 4:e00360-13. http://dx.doi.org/10.1128/mBio.00360-13.
39. Tucker AT, Nowicki EM, Boll JM, Knauf GA, Burdis NC, Trent MS, DaviesBW. 2014. Defining gene-phenotype relationships in Acinetobacter baumannii through one-step chromosomal gene inactivation. mBio 5:e01313–14. http://dx.doi.org/10.1128/mBio.01313-14.
40. Eijkelkamp BA, Stroeher UH, Hassan KA, Papadimitrious MS, Paulsen IT, Brown MH. 2011. Adherence and motility characteristics of clinical Acinetobacter baumannii isolates. FEMS Microbiol Lett 323:44–51. http://dx.doi.org/10.1111/j.1574-6968.2011.02362.x.
41. Srinivasan VB, Rajamohan G, Pancholi P, Marcon M, Gebreyes WA. 2011. Molecular cloning and functional characterization of two novel membrane fusion proteins in conferring antimicrobial resistance in Acinetobacter baumannii. J Antimicrob Chemother 66:499-504. http://dx.doi.org/10.1093/jac/dkq469.
42. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.
43. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. 2011. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 55: 3743–3751. http://dx.doi.org/10.1128/AAC.00256-11.
44. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 55:3370-3379. http://dx.doi.org/10.1128/AAC.00079-11.
45. Mihara K, Tanabe T, Yamakawa Y, Funahashi T, Nakao H, Narimatsu S, Yamamoto S. 2004. Identification and transcriptional organization of a gene cluster involved in biosynthesis and transport of acinetobactin, a siderophore produced by Acinetobacter baumannii ATCC 19606T. Microbiology 150:2587–2597. http://dx.doi.org/10.1099/mic.0.27141-0.
46. Magnet S, Courvalin P, Lambert T. 2001. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454 Antimicrob Agents Chemother 45: 3375–3380. http://dx.doi.org/10.1128/AAC.45.12.3375-3380.2001.
47. Yoon E-J, Chabane YN, Goussard S, Snesrud E, Courvalin P, Dé E, Grillot-Courvalin C. 2015. Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii. mBio 6:e00309-15. http://dx.doi.org/10.1128/mBio.00309-15.
48. Baugh S, Ekanayaka AS, Piddock LJ, Webber MA. 2012. Loss of or inhibition of all multidrug resistance efflux pumps of Salmonella enterica serovar Typhimurium results in impaired ability to form a biofilm. J Antimicrob Chemother 67:2409-2417. http://dx.doi.org/10.1093/jac/dks228.
49. Elkins CA, Nikaido H. 2003. Chimeric analysis of AcrA function reveals the importance of its C-terminal domain in its interaction with the AcrB multidrug efflux pump. J Bacteriol 185:5349-5356. http://dx.doi.org/10.1128/JB.185.18.5349-5356.2003.
50. Smith HE, Blair JM. 2014. Redundancy in the periplasmic adaptor proteins AcrA and AcrE provides resilience and an ability to export substrates of multidrug efflux. J Antimicrob Chemother 69:982–987. http://dx.doi.org/10.1093/jac/dkt481.
51. Koh TH, Tan TT, Khoo CT, Ng SY, Tan TY, Hsu LY, Ooi EE, Van Der Reijden TJ, Dijkshoorn L. 2012. Acinetobacter calcoaceticus-Acinetobacter baumannii complex species in clinical specimens in Singapore. Epidemiol Infect 140:535–538. http://dx.doi.org/10.1017/S0950268811001129.
52. Kersey PJ, Allen JE, Christensen M, Davis P, Falin LJ, Grabmueller C, Hughes DS, Humphrey J, Kerhornou A, Khobova J, Langridge N, McDowall MD, Maheswari U, Maslen G, Nuhn M, Ong CK, Paulini M, Pedro H, Toneva I, Tuli MA, Walts B, Williams G, Wilson D, Youens- Clark K, Monaco MK, Stein J, Wei X, Ware D, Bolser DM, Howe KL, Kulesha E, Lawson D, Staines DM. 2014. Ensembl genomes 2013: scaling up access to genome-wide data. Nucleic Acids Res 42:D546–D552. http://dx.doi.org/10.1093/nar/gkt979.
53. Richmond GE, Chua KL, Piddock LJ. 2013. Efflux in Acinetobacter baumannii can be determined by measuring accumulation of H33342 (bisbenzimide). J Antimicrob Chemother 68:1594–1600. http://dx.doi.org/10.1093/jac/dkt052.
54. Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(Suppl 1):5–16. http://dx.doi.org/10.1093/jac/48.suppl_1.5.
55. EUCAST. 2015. The European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters, version 5.0. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland. http://www.eucast.org/clinical_breakpoints/.
56. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771–1776.
57. Li X, Gorle AK, Ainsworth TD, Heimann K, Woodward CE, Grant Collins J, Richard Keene F. 2015. RNA and DNA binding of inert oligonuclear ruthenium(II) complexes in live eukaryotic cells. Dalton Trans 44:3594–3603. http://dx.doi.org/10.1039/C4DT02575J.
58. Haimovich B, Tanaka JC. 1995. Magainin-induced cytotoxicity in eukaryotic cells: kinetics, dose-response and channel characteristics. Biochim Biophys Acta 1240:149-158. http://dx.doi.org/10.1016/0005-2736(95)00204-9.
59. Tsai YJ, Lin YC, Wu WB, Chiu PH, Lin BJ, Hao SP. 2013. Biofilm formations in nasopharyngeal tissues of patients with nasopharyngeal osteoradionecrosis. Otolaryngol Head Neck Surg 148:633-636. http://dx.doi.org/10.1177/0194599812474971.
60. Wand ME, Müller CM, Titball RW, Michell SL. 2011. Macrophage and Galleria mellonella infection models reflect the virulence of naturally occurring isolates of B. pseudomallei, B. thailandensis and B. oklahomensis. BMC Microbiol 11:11. http://dx.doi.org/10.1186/1471-2180-11-11.